<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Judgment</title>
	<atom:link href="http://www.tapanray.in/tag/judgment/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug, Patent and Hype: Quo Vadis Pharma Innovation?</title>
		<link>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-patent-and-hype-quo-vadis-pharma-innovation</link>
		<comments>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/#comments</comments>
		<pubDate>Sun, 20 Oct 2013 18:30:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[discover]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Hype]]></category>
		<category><![CDATA[indications]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[Nature]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patentable]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Prescire]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Reviews]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Section(3d)]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2704</guid>
		<description><![CDATA[A recent research report reveals, though the pharmaceutical companies in the United States since mid 2000 have spent over US$ 50 billion every year to discover new drugs, they have very rarely been able to invent something, which can be called significant &#8230; <a href="http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Balancing IPR with Public Health Interest: Brickbats, Power Play and Bouquets</title>
		<link>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets</link>
		<comments>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/#comments</comments>
		<pubDate>Mon, 01 Jul 2013 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Argentina]]></category>
		<category><![CDATA[Balancing]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[bouquets]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[brickbats]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[Carlos]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[Correa]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[inventive]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[Leash]]></category>
		<category><![CDATA[Leashing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[power play]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[raging]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reasonably]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[Section(3d)]]></category>
		<category><![CDATA[Section2(ja)]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USIBC]]></category>
		<category><![CDATA[wasteful]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WOW]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2691</guid>
		<description><![CDATA[It is now a widely accepted dictum that Intellectual Property Rights (IPR), especially pharma patents, help fostering innovation and is critical in meeting unmet needs of the patients. However, the moot question still remains, what type pharmaceutical invention, should deserve &#8230; <a href="http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does the Landmark Glivec Judgment Discourage Innovation in India?</title>
		<link>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-landmark-glivec-judgment-discourage-innovation-in-india</link>
		<comments>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/#comments</comments>
		<pubDate>Mon, 08 Apr 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[191]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Cipal]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gefitinib. Roche]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[highcourt]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[interpretation]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Janumet]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[knowledge]]></category>
		<category><![CDATA[landmark]]></category>
		<category><![CDATA[medicines. imatinib]]></category>
		<category><![CDATA[mesylate]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pegasys]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[stutent]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[with]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[Zita]]></category>
		<category><![CDATA[Zita-Met]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2150</guid>
		<description><![CDATA[No, I do not think so. The 112 pages well articulated judgment of the Supreme Court of India delivered on April 1, 2013, does not even remotely discourage innovation in India, including much talked about ‘incremental innovation’. This landmark judgment &#8230; <a href="http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Recent Bayer Case Judgment: Patent Linkage: Encouraging Innovation in India</title>
		<link>http://www.tapanray.in/recent-bayer-case-judgment-patent-linkage-encouraging-innovation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=recent-bayer-case-judgment-patent-linkage-encouraging-innovation-in-india</link>
		<comments>http://www.tapanray.in/recent-bayer-case-judgment-patent-linkage-encouraging-innovation-in-india/#comments</comments>
		<pubDate>Mon, 24 Aug 2009 00:30:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[encouraging]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=800</guid>
		<description><![CDATA[Delhi High Court turned down the request of Bayer Corporation in August 18, 2009 to link patent status of its kidney cancer drug Nexavar (sorefenib tosylate) with the marketing approval of the generic equivalent of the same patented molecule manufactured &#8230; <a href="http://www.tapanray.in/recent-bayer-case-judgment-patent-linkage-encouraging-innovation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/recent-bayer-case-judgment-patent-linkage-encouraging-innovation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
